Appropriate duration of intravenous treatment of candidemia and timing of step down to oral therapy in non-neutropenic patients

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

In this review, we have analyzed the available literature pertaining to the total duration of intravenous (IV) therapy and the appropriate timing of step down to oral therapy in the management of candidemia. Overview of the guidelines and literature seem to indicate that a minimum of 14 days of antifungal therapy is required in the treatment of candidemia without deeply seated infection. However, this was never based on evidence. Furthermore, step down to oral therapy seems to be dependent on the clinical stability criteria of the patient with candidemia after 4 to 7 days of IV therapy. Further studies are required to evaluate the appropriate total duration of IV therapy, appropriate timing of step down to oral therapy and to validate the clinical criteria that would allow the switch to happen.

Original languageEnglish (US)
Article numbere2018028
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume10
Issue number1
DOIs
StatePublished - 2018

Keywords

  • Candidemia
  • Intravenous treatment
  • Non-nuetropenic patients

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Appropriate duration of intravenous treatment of candidemia and timing of step down to oral therapy in non-neutropenic patients'. Together they form a unique fingerprint.

Cite this